What Editas Medicine does

Editas Medicine is a clinical-stage genome editing company that develops CRISPR-based genomic medicines for serious diseases. The company is publicly traded on NASDAQ under ticker EDIT, headquartered in Cambridge, Massachusetts (with a secondary office in Boulder, Colorado), and employs approximately 246 people as of March 2026. It was founded around 2013-2015 by CRISPR pioneers Feng Zhang, George Church, Keith Joung, and David Liu. Following a major December 2024 strategic reset that reduced headcount by roughly 65% and abandoned the ex vivo reni-cel (EDIT-301) program for sickle cell disease and beta thalassemia, the company has repositioned around EDIT-401, an in vivo CRISPR gene editing medicine targeting the LDLR gene for durable LDL cholesterol reduction in patients with hyperlipidemia and atherosclerotic cardiovascular disease.

The company's technology platform spans dual CRISPR modalities — Cas9 (using both aureus and pyogenes variants) and Cas12a/Cpf1 — supported by an exclusive license to the foundational Cas9 and Cas12a patent estates from Harvard University and the Broad Institute. Proprietary platform components include SLEEK, an engineered AsCas12a approach enabling high-efficiency multi-transgene knock-in for next-generation cell therapies; UDiTaS, an analytical methodology for simultaneous measurement of on-target editing, off-target editing, and structural changes; and targeted lipid nanoparticle (tLNP) delivery systems for tissue-specific in vivo editing of hematopoietic stem cells, liver, and other tissues. Preclinical NHP data for EDIT-401 demonstrated ≥90% mean LDL-C reduction with durability through approximately six months at a 1.5 mg/kg therapeutic dose.

Editas is pre-commercial and generates revenue exclusively through collaboration and licensing agreements. The 2025 revenue base of $40.5 million (+25.4% YoY) reflects upfront and milestone payments from Bristol Myers Squibb (alpha-beta T-cell oncology), Genevant Sciences ($238M upfront in October 2024 for Cas12a-LNP delivery), Vertex Pharmaceuticals (historical CASGEVY milestones), and Immatics (gamma-delta T-cells). The company posted a $160.1 million net loss in 2025 and held $146.6 million in cash at year-end, projected to fund operations into Q3 2027 before a May 2026 $125 million public offering (with warrants potentially totaling $319.4 million). Future product commercialization is planned through hospital/clinic administration of one-time gene editing treatments, likely leveraging strategic partnerships with larger pharmaceutical companies.

Name

Editas Medicine

Legal name

Editas Medicine, Inc.

Website

https://editasmedicine.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

Editas Medicine is a clinical-stage CRISPR gene editing company developing in vivo genomic medicines for serious diseases. Following a 2024 strategic pivot from ex vivo programs, its lead candidate EDIT-401 targets durable LDL cholesterol reduction in hyperlipidemia patients.

Ownership category

akta.pro rank

Product category

Gene Editing Therapeutics

NAICS

Scientific Research and Development Services (5417), Medicinal and Botanical Manufacturing (325411)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)

akta.pro primary industry

Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)

akta.pro secondary industries

Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

Keywords

• Genome editing
• CRISPR therapeutics
• Gene editing medicines
• In vivo gene editing
• Ex vivo cell therapy

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Collaboration and Partnership Revenue: Pre-commercial biotech company generating revenue primarily through strategic partnerships and collaboration agreements. Revenue includes upfront payments, milestone payments, and potentially royalties from pharmaceutical partners. The company reported $40.5 million in revenue in 2025 with 25.4% year-over-year growth, though also posted a net loss of $160.1 million.
2. Future Product Sales: Once clinical candidates receive regulatory approval, the company plans to commercialize gene editing medicines directly. Currently pre-revenue from product sales as all programs are in preclinical or early clinical stages.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Editas Medicine is a clinical-stage genome editing company developing CRISPR-based gene editing medicines to treat serious diseases. The company's pipeline includes in vivo gene editing candidates, with its lead candidate EDIT-401 focused on treating hyperlipidemia. Editas operates an integrated platform combining proprietary gene editing technologies (CRISPR/Cas9, CRISPR/Cas12a, SLEEK, UDiTaS) with targeted lipid nanoparticle delivery systems to develop both in vivo and ex vivo therapeutic candidates.

Product overview

Editas Medicine is a clinical-stage gene editing company developing a pipeline of CRISPR-based genomic medicines. The company operates two core technology platforms: CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) gene editing systems, enhanced with proprietary SLEEK gene editing for cell therapies and UDiTaS analytical methodology. The clinical pipeline centers on EDIT-401, an in vivo gene editing candidate for hyperlipidemia and ASCVD, representing the company's strategic pivot from ex vivo programs. EDIT-301 (reni-cel) for sickle cell disease was previously in development but the program was abandoned. Delivery technologies include targeted lipid nanoparticles (tLNPs) for tissue-specific in vivo editing. The company maintains partnerships with Bristol Myers Squibb for ex vivo cell medicines and Genevant Sciences for LNP delivery technology.

Differentiator

Problem solved

Functional benefit

Brands

• SLEEK: An optimized approach to developing next generation cell therapy medicines for cancer and other serious diseases, enabling high efficiency multi-transgene knock-in of iPSCs, T cells, and NK cells.
• UDiTaS

Products and services

• EDIT-401

Quantifiable outcome

• EDIT-401 demonstrated ~90% mean reduction in LDL-C in non-human primates in preclinical studies (standard of care shows 40-60% reduction)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Genevant SciencescoreStrategic or Co-development Partner · 21 October 2024Collaboration and nonexclusive license agreement to develop gene editing therapeutics using CRISPR Cas12a and lipid nanoparticle (LNP) technology. Deal includes upfront payment of $238 million and milestone payments with royalties on future sales. Partnership aims to accelerate delivery and safety of genome editing medicines for rare diseases.
• Bristol Myers SquibbcoreStrategic or Co-development PartnerStrategic partnership with Bristol Myers Squibb, a leader in oncology medicines, to develop next-generation ex vivo gene edited cell medicines and advance the field of cancer immunotherapy. The companies have demonstrated ability to edit multiple gene targets individually and in combination for T-cell medicines.
• ImmaticsminorStrategic or Co-development PartnerPartnership with Immatics N.V. for development of gamma-delta T-cell medicines for cancer treatment, leveraging Editas' gene editing capabilities combined with Immatics' T-cell receptor platform.
• Harvard University / Broad InstitutecoreTechnology or IntegrationExclusive licensing relationships for foundational CRISPR patent estates (Cas9 and Cas12a) from Harvard University and Broad Institute of MIT and Harvard, enabling Editas to develop human medicines using these gene editing technologies and to issue sublicenses to other companies.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Prime Medicine: Clinical-stage company developing prime editing, a CRISPR-derived next-generation gene editing modality. Comparable platform-stage company targeting genetic diseases with novel editing approaches.
• Verve Therapeutics: In vivo gene editing company focused on cardiovascular disease, including LDL-C reduction (VERV-102) — direct competitor to Editas's EDIT-401 in the same patient population and indication.
• Intellia Therapeutics: Clinical-stage CRISPR gene editing company developing both in vivo (NTLA-2001/2002 for transthyretin amyloidosis and HAE) and ex vivo programs. Closely comparable in vivo platform approach and pipeline stage.
• Sangamo Therapeutics: Earlier-stage genome editing company using zinc finger nucleases and other engineered nucleases. Operates in the same genomic medicine space with similar clinical-stage profile and partnership-driven model.
• Beam Therapeutics: Clinical-stage base editing company applying CRISPR-derived precision editing to hemoglobinopathies and other genetic diseases. Directly competes in next-generation gene editing modality space.
• CRISPR Therapeutics: Direct CRISPR/Cas9 gene editing peer developing Casgevy (with Vertex) for SCD/beta-thalassemia and in vivo programs. Competes head-to-head with Editas in CRISPR-based therapeutics and targets overlapping patient populations.

Emerging players

• Moderna: mRNA/LNP delivery platform company with growing gene editing ambitions. Comparable in delivery technology (LNP) overlap with Editas's tLNP platform and a likely competitor/partner for in vivo editing delivery.
• Caribou Biosciences: Clinical-stage CRISPR gene editing company (allogeneic CAR-T cell therapies). Comparable platform-stage competitor in CRISPR cell therapy development, with partial overlap in oncology.

Broad incumbents

• Bristol Myers Squibb: Strategic partner for Editas's ex vivo alpha-beta T-cell oncology programs. Broad oncology/cell therapy incumbent with overlapping cell therapy ambitions but far larger commercial scale.
• Vertex Pharmaceuticals: Large-cap biopharmaceutical partner and indirect competitor; commercialized Casgevy (ex vivo CRISPR therapy for SCD) in partnership with CRISPR Therapeutics — overlapping with Editas's abandoned reni-cel program and a potential acquirer/partner for future in vivo assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/editasmed
• LinkedInlinkedin.com/company/editas-medicine
• Facebookfacebook.com/Editas-Medicine-343802536259898

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds8 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Editas Medicine